Company intelligence / Profile preview

LEO Pharma

Ownership: Private
Employees: ~5000
Development stage: Other

Overview

LEO Pharma has a robust pipeline focused on innovative treatments for skin diseases. Its lead assets include tralokinumab (an anti–IL‑13 mAb for atopic dermatitis) and delgocitinib (a topical pan-JAK inhibitor for chronic hand eczema). The company also develops new biologics and small molecules targeting key inflammatory pathways in dermatology. Several products are approved or in late-stage trials.

Therapeutic areas: ImmunologyDermatology
Modalities: Topical therapiessmall moleculesmonoclonal antibodies (mAbs)oral tabletsinjectable biologics
Industry: Biotech

Drug pipeline

51 assets

tralokinumab

Approved

50 more assets in the full pipeline.

Partnerships

Collaborations with academic institutions and industry partners to advance dermatological research; specific partners not detailed in provided results but referenced generally.

Beyond the preview

Go deeper on LEO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEO Pharma.